Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of midazolam, hydroxyzine, nitrous oxide, and oxygen is a multi-modal pharmacological sedation regimen primarily utilized in pediatric dentistry to manage uncooperative behavior in children. This regimen leverages the synergistic effects of three distinct sedative agents. Midazolam, a short-acting benzodiazepine, provides anxiolysis and anterograde amnesia by acting as a positive allosteric modulator of the GABA-A receptor. Hydroxyzine, a first-generation antihistamine, contributes supplemental sedation and antiemetic properties through its antagonism of the histamine H1 receptor. Nitrous oxide, an inhaled anesthetic, provides rapid-onset conscious sedation and analgesia, likely through NMDA receptor antagonism and GABA-A receptor modulation. The regimen typically involves oral premedication with midazolam and hydroxyzine followed by the inhalation of a nitrous oxide/oxygen mixture during the dental procedure. Tishreen University has sponsored clinical research evaluating the efficacy of this specific combination compared to oral sedation alone in pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on midazolam + hydroxyzine + nitrous oxide + oxygen.